Stephen F. Betz - 01 Sep 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Scientific Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
01 Sep 2022
Net transactions value
-$43,390
Form type
4
Filing time
06 Sep 2022, 16:20:16 UTC
Previous filing
04 May 2022
Next filing
09 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Other $14,723 +1,336 +1.2% $11.02 108,934 20 May 2022 Direct F1
transaction CRNX Common Stock Sale $58,112 -3,126 -2.9% $18.59 105,808 01 Sep 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).
F2 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.